Biotechnology
Cancer
Therapies
Usa
Pharmaceuticals
Development
M&A Advisory
Lazard
Full Credential Description
OncoGeneX Pharmaceuticals. United States. Announced Date 16/03/2012. Closed Date 21/03/2012. Deal value: $50m. Confidentially marketed public offering of common stock. Industry: OncoGeneX Pharmaceuticals is a biotechnology company focused on developing therapies for cancer treatment.